The adjuvant treatment of resected head and neck squamous cell carcinoma (HNSCC) is guided by the European Organisation for Research and Treatment of Cancer (EORTC) 22931 and Radiation Therapy Oncology Group (RTOG) 95-01 randomized clinical trials.
1,2 Both trials randomized patients with at least 1 adverse prognostic factor after definitive surgery to adjuvant radiotherapy (RT) or cisplatin-based chemoradiotherapy (CRT), and both demonstrated a progression-free survival (PFS) benefit with CRT. The specific adverse risk features qualifying patients for each trial were variable, but an exploratory combined analysis
3 suggested that extracapsular extension (ECE) and positive surgical margins were the most significant prognostic factors, and patients with 1 of these 2 features derived benefit from CRT.